Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunotherapy. 2013 Mar;5(3):265-99. doi: 10.2217/imt.13.10.

Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.

Author information

1
Department of Medicine at School of Medicine, University of Alabama, Birmingham, AL, USA. jasvinder.md@gmail.com

Abstract

A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed. An increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have a modestly better safety profile in terms of tuberculosis and opportunistic infections, and infliximab posing a higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use.

PMID:
23444956
PMCID:
PMC3779683
DOI:
10.2217/imt.13.10
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center